Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to treat cancer and autoimmune diseases. Founded in 2020 and headquartered in Cambridge, Massachusetts (with additional operations in Zurich, Switzerland), Repertoire was founded under Flagship Pioneering. The company's proprietary DECODE platform provides comprehensive insights into the immune synapse — the central hardware of the adaptive immune system — identifying T cell receptor (TCR) and antigen epitope pairs across all human HLAs. Using these discovered 'immune codes,' Repertoire designs TCR bispecific molecules, mRNA cancer vaccines, and mRNA tolerizing vaccines to program the immune system to eliminate tumors and restore immune balance in autoimmune patients. The company has established collaborations with Eli Lilly, Genentech, and Pfizer, and is advancing a pipeline of candidates in immuno-oncology and autoimmune disease indications.